LQDA Liquidia Corporation

Liquidia to Present at the Stifel 2024 Healthcare Conference

Liquidia to Present at the Stifel 2024 Healthcare Conference

MORRISVILLE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET.

Access to the live webcasts will be available to investors and other interested parties via Liquidia’s website at .

An archived, recorded version of each presentation will be available on Liquidia’s website for at least 30 days following the event.

About Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).  The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit .

Contact Information

Investors:

Jason Adair

919.328.4350

Media:

Patrick Wallace

919.328.4383



EN
12/11/2024

Underlying

LQDALiquidia Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Liquidia Corporation

 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation Reports Third Quarter 2024 Financial Results and ...

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)U.S. Supreme Court rejected final appeal of ‘793 patent decision, marking victories with respect to three patents originally asserted final and not subject to further appealStrengthened balance sheet by raising approximately $100 million in additional capital MORRISVILLE, N.C., Nov...

November 13, 2024 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia to Present at the Stifel 2024 Healthcare Conference

Liquidia to Present at the Stifel 2024 Healthcare Conference MORRISVILLE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that the company will present at the Stifel 2024 Healthcare Conference in New York City on Tuesday, November 19, 2024, from 3:00 – 3:30 p.m. ET. Access to the live webcasts will be available to investors and other interested parties via Liquidia’s website at . An archived, recorded version of each presentation will b...

November 12, 2024 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Report Third Quarter 2024 Financial Results on...

Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024 MORRISVILLE, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today it will now report its third quarter 2024 financial results on Wednesday, November 13, 2024. The date has been moved to accommodate for SEC filing rules impacted by the federal holiday observed on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to di...

November 6, 2024 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

Liquidia Corporation to Report Third Quarter 2024 Financial Results on...

Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024 MORRISVILLE, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2024 financial results on Monday, November 11, 2024. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The live webcast will be available on Liquidia's website at . A rebroadc...

November 4, 2024 1 EN
 PRESS RELEASE
Free
LQDA Liquidia Corpor...

United States Supreme Court Declines to Review Rulings that Invalidate...

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent U.S. Supreme Court denied United Therapeutics’ petition to appeal rulings that found all claims of U.S. Patent No. 10,716,793 (‘793 Patent) were invalidDecisions that Liquidia does not infringe any valid claims of the three patents originally asserted by United Therapeutics are now final and not subject to further appeal MORRISVILLE, N.C., Oct. 07, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary dis...

October 7, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch